This vaccine protects against tick-borne encephalitis in people over the age of 1 year.
Formulary Watch
Latest News
All News
Advertisement
The multiple myeloma therapy now has a permanent J code under Medicare Part B.
Trials result show that Lyumjev compares favorably to Humalog.
All stakeholders together incur about $93.3 billion in costs for implementing, contesting, and navigating drug utilization management.
This is the first approval of generic version of Chantix, and it comes just weeks after a recall of the brand-name drug.
The potassium-lowering agent was associated with a 20% relative reduction in costs related to outpatient, inpatient, and emergency department visits.
Four products on the preferred list this year will be excluded next year.
The VA recommends against offering this agent to patients with Alzheimer’s dementia, mild or otherwise.
The program and proposed integrations could produce $15 million in savings annually.
Advertisement
The decision follows an advisory committee recommendation not to approve because of safety issues.
Libtayo also reduced the risk of death by 29% compared with chemotherapy alone.
A decision on the plaque psoriasis therapy is expected in the second quarter of 2022.
The graft-versus-host disease therapy has also been added to NCCN Guidelines.
Previously patients administered as two, 75-mg shots. Now they can inject a single 150-mg dose.
The bottles have a counterfeit foil seal or label and contain an incorrect number of tablets.
Current drug shortages based on FDA data, prepared by Formulary Watch.
The therapy for HIV-related pneumonia was exposed to cold weather during shipment.
The therapy can now be used for post-exposure prevention in people at high risk for progression to severe disease.
The PDUFA date has been set for December 4, 2021; FDA has designated this as a Priority Review.
The PDUFA date for this indication is December 4, 2021.
A single application targets the infection without entering the circulatory system.
The FDA is expected to make a decision on this indication by December 1, 2021.
The therapy had received accelerated approval in 2011 but a phase 3 confirmatory trial found it did not meet the end point of progression-free survival.
The sickle cell disease therapy will now be on the Preferred Drug List.
This is the first new approval for lupus in a decade.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
3
Biosimilar competition could surpass IRA-negotiated savings by year three
4
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
5
